<DOC>
	<DOCNO>NCT01265992</DOCNO>
	<brief_summary>Paricalcitol capsule ( ZemplarÂ® ) receive market authorization Sweden late 2007 prevention treatment secondary hyperparathyroidism patient Stage 3 &amp; 4 Chronic Kidney Disease ( CKD ) . Accordingly , additional data need evaluate effectiveness safety paricalcitol therapy condition usual clinical care Sweden . This observational study design collect data evaluate safety effectiveness 6 month therapy paricalcitol capsule prescribe patient CKD Stages 3-5 yet dialysis . Data also collect patient quality life cost associate patient care .</brief_summary>
	<brief_title>Study Assess Patient Management Practices Quality Life With Paricalcitol Capsules Treatment Secondary Hyperparathyroidism Stage 3-5 Chronic Kidney Disease Patients Not Yet Dialysis</brief_title>
	<detailed_description>This observational study design collect data evaluate safety effectiveness 6 month therapy paricalcitol capsule prescribe accordance term market authorization patient Chronic Kidney Disease ( CKD ) Stages 3-5 yet dialysis . Data also collect patient quality life cost associate patient care . A retrospective chart review patient laboratory medication history provide historical data determine driver initiation paricalcitol therapy . The primary goal post-marketing observational study ( PMOS ) characterize prescribe habit patient management practice physicians prescribe paricalcitol capsule assess metabolic safety effectiveness paricalcitol capsule treatment secondary hyperparathyroidism Stage 3-5 CKD patient yet dialysis condition usual clinical care . Focus examine practice dose titration early stage CKD , understand real-world management intact parathyroid hormone level , understand real-world incidence management abnormality serum calcium phosphate , examine patient bone mineral profile medical history understand driver paricalcitol capsule use . Patients prescribed paricalcitol therapy first time ask participate study . Enrolled patient follow 6 month .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Patients must sign Informed Consent Form prior inclusion study Patients satisfy Swedish Summary Product Characteristics ( SPC ) paricalcitol capsule www.fass.se Patients must 18 year old diagnosis secondary hyperparathyroidism associate Chronic Kidney Disease ( CKD ) Stages 3 5 ( estimate Glomerular Filtration Rate 1059 Modification Diet Renal Disease ) yet dialysis Patients stable condition life expectancy least 6 month Patients expect transplanted initiate dialysis least 6 month Patients CKD receive dialysis Patients contraindicate paricalcitol capsule describe SPC Treatment paricalcitol 20 day prior study enrollment History drug alcohol abuse within 6 month prior inclusion History noncompliance medication medical history ( i.e . psychiatric ) could enhance noncompliance medication determine investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Secondary hyperparathyroidism</keyword>
	<keyword>Mineral Bone Disorder ( CKD-MBD )</keyword>
	<keyword>Chronic Kidney Disease</keyword>
</DOC>